Summary Serial image guided 31P magnetic resonance spectroscopy (MRS) studies were performed in eight patients with non-Hodgkin's lymphoma to determine the changes in phosphorus metabolites that occur in vivo in response to chemotherapy. Pre-treatment spectral characteristics were different in high and low grade lymphoma. A larger inorganic phosphate (Pi) peak was seen in high grade NHL relative to phosphomonoesters (PME) or P adenosine triphosphate (PATP), producing significant differences in the PME/Pi and Pi/PATP metabolite ratios, and probably reflecting a larger hypoxic cell fraction within the high grade lymphomas. Consistent Chance, 1986; Daly & Cohen, 1989) . It is only relatively recently, however, with the advent of high field (1.5 Tesla), whole body, combined imaging and spectroscopy systems, that knowledge gained from these studies could be applied to the study of human tumours in vivo.
Magnetic resonance spectroscopy provides a totally noninvasive means of investigating the chemistry of human tissues and organs. 31P MRS allows the metabolites involved in bioenergetic pathways and phospholipid turnover to be monitored, as well as providing a non-invasive means of measuring tissue pH.
High resolution MRS studies on tumour cell lines, and tumours implanted in rodents have shown the potential of 31p MRS in cancer (Evanochko et al., 1984; Sostman et al., 1984; Maris & Chance, 1986; Daly & Cohen, 1989) . It is only relatively recently, however, with the advent of high field (1.5 Tesla), whole body, combined imaging and spectroscopy systems, that knowledge gained from these studies could be applied to the study of human tumours in vivo.
The ability to monitor biochemical changes in human tumours non-invasively raises the possibility of the early prediction of treatment response, and monitoring for development of drug resistance (Cohen et al., 1986) . In vivo MRS studies assessing tumour response to therapy are limited; the histological types of tumour studied have been very varied, and the use of different MRS data acquisition and processing techniques has made comparisons between studies difficult. These studies have recently been reviewed (Daly & Cohen, 1989; Bottomly, 1989; Steen, 1989) .
We have used an image guided slice selective MRS localisation technique to obtain well resolved 31p spectra serially from eight patients with non-Hodgkin's lymphoma (NHL). The aim of this preliminary study being three-fold; to identify the pre-treatment phosphorus characteristics of low and high grade NHL; to establish by serial studies in the early period after the commencement of chemotherapy the 31p MRS characteristics that are associated with, or possibly predictive of a response to therapy; and finally to identify the time period in which these changes occur in relation to chemotherapy.
Patients and methods
Eight patients with newly diagnosed NHL were studied. Local ethical committee approval was obtained and all patients gave written consent. MRS examinations were performed before starting chemotherapy and serially at various times after commencing treatment. (Glazer et al., 1989; Smith et al., 1990 (Taylor et al., 1983) .
The significance of differences in pre-treatment metabolite ratios between high and low grade NHL was assessed using the Mann-Whitney U test.
Results
Pre-treatment studies Figure 1 shows an axial gradient echo image of the lower abdomen in a patient with low grade NHL. The position of the surface coil and the slice 4 cm off the coil from which the spectrum used for metabolite estimation was obtained is shown. Figure 2 shows the spectra obtained with the ID-CSI technique from this patient. Note the spectrum from the superficial slice immediately adjacent to the surface coil is consistent with that from muscle in the anterior abdominal wall (prominent phosphocreatine (PCr) and three resonances of adenosine triphosphate (ATP)). The high energy substrate PCr is absent from the spectra localised to the lymphoma (slices at 3, 4 and 5 cm off the surface coil), and a very prominent phosphomonoester (PME) peak in relation to PATP or inorganic phosphate (Pi) is present. Well resolved spectra with acceptable signal to noise were obtained in all patients.
Pre-treatment metabolite ratios are shown in Table II . Low and high grade lymphomas could be distinguished on the basis of spectral characteristics with the high grade tumours having a larger Pi peak relative to PME or PATP (Figure 3 ). This produced significant differences in the PME/Pi (P = 0.018) and Pi/PATP (P = 0.036) metabolite ratios between the two groups. The PME/Pi ratio produced the best separation between low and high grade lymphomas.
Post-treatment studies
All patients had serial studies performed after commencing chemotherapy. Changes in tumour metabolites were seen prior to reductions in tumour size in all patients except patient 7, whose first follow-up study at day 28 was after a reduction in tumour size had occurred.
In low grade lymphoma treated with oral alkylating agents (patients 1-4) very consistent metabolite changes were seen after therapy was commenced. These changes consisted of a relative increase in Pi peak area and decrease in PATP, followed by increases in the phosphodiesters (PDE). Alterations in tumour metabolism were detected by 31P MRS between days 10 and 27 of commencing therapy in patients with low grade NHL. Figure 4 illustrates the phosphorus metabolite changes seen in patient 1 after starting chemotherapy, and their relationship to changes in tumour size.
Patient 5 with bulky abdominal disease treated with more intensive combination chemotherapy (CHOP) showed a similar pattern of change in metabolites, however they were detected much earlier by day 5.
The metabolic changes seen in high grade abdominal lymphoma (patient 6) treated with intravenous combination chemotherapy are illustrated in Figure 5 . By day 3 marked changes in Pi and PDE were already detectable, and were subsequently followed by a large reduction in tumour volume by day 7. Immediately before the next course of therapy relative metabolite levels had returned to near pre-treatment levels.
In patient 8 alterations in metabolites within 24 h of commencing therapy were detected with a relative increase in PDE and a decrease in PATP. This patient was studied very closely through the first three weeks of therapy with a multiagent chemotherapeutic regime, PCOMMB (Philips, 1987) . In this regime pairs of chemotherapeutic agents are given at weekly intervals and these studies allowed the response to each weekly drug combination to be assessed. A response to each drug combination was seen with a maximal rise in the PDE/PATP metabolite ratio by the second or third day following each weekly treatment (Figure 6 ). A similar but less marked pattern of change was also seen in the Pi/PATP ratio. Immediately before the next treatment,-metabolite levels were approaching pre-treatment baseline values.
Of the metabolite ratios examined the most consistent alterations with treatment were observed in the PDE/PATP ratio. All tumours showed marked increases in the PDE/ PATP metabolite ratio (51-266%) with therapy. These Volume change -10% 7.23 7.23 7.31 7.6 changes were seen before tumour shrinkage in all patients except patient 7. The maximum changes in this ratio and their relation to time after commencing chemotherapy are summarised in Figure 7 .
Pre-treatment pH values are shown in Table II . pH values were normal or alkaline in low grade lymphoma (range 7.16-7.39 pH units). The range of pH values was greater in high grade . No set pattern of pH change was seen with treatment, but pH remained very alkaline in some cases even in the presence of increased Pi (Figure 4 ).
Discussion
The potential of MRS to assess treatment response in tumours has been well documented in animal models (Evanochko et al., 1984; Sostman et al., 1984; Maris & Chance, 1986; Daly & Cohen, 1989; Steen et al., 1989) . However, due to difficulties in performing in vivo MRS (low MR sensitivity of phosphorus containing compounds, low signal-to-noise ratio of in vivo spectra, poor spatial localisation of the MR signal, long examination time and patient compliance), only a few studies have been reported assessing early treatment response in human tumours (Ng et al., 1987 (Ng et al., , 1989a Semmler et al., 1988a, b) . These studies all used whole volume MRS localisation techniques therefore the spectra acquired from some of the tumours would have been contaminated with signal from surrounding non-tumour tissue. Phase encoding spectroscopic techniques have been used to assess treatment response in two patients with B cell nonHodgkin's lymphoma of bone (Bryant et al., 1988) .
We have previously shown that the lD-CSI technique is a reproducible method of obtaining localised in vivo 31P spectra from human organs (Glazer et al., 1989; Smith et al., 1990) . It is important to note, however, that the metabolite ratios reported are relative ratios and are not absolute metabolite concentrations.
As lymphomas generally respond well to chemotherapy, and frequently present with very bulky superficial disease they are suitable to be studied by currently available MRS localisation techniques. This is the largest reported series of patients with similar tumour types studied with an image guided spectroscopic localisation technique to assess the 31P MRS characteristics that are associated with a response to chemotherapy.
Very reproducible spectral patterns were seen in both groups of lymphoma. The major pre-treatment difference in 31P characteristics between high and low grade lymphomas related to tumour bioenergetics. The Pi peak area was larger in relation to PME or PATP in high grade lymphoma. This presumably represents a larger hypoxic cell fraction in high grade lymphoma and may be due to out growth of tumour blood supply.
One may have expected the pH measured in some of these tumours to be more acidic due to lactate production but an alkaline pH is consistent with pH measurements reported for other human tumours (Ng et al., 1989b; Oberhaensli et al., 1986) . Mechanisms proposed for the production of this alkaline tumour pH include raised intracellular pH in relation to cell growth and activation of Na +/H+ exchange (Schuldiner & Rozengurt, 1982; Hesketh et al., 1985) . The variation in pH in these lymphomas may reflect aspects of tumour heterogeneity, or have been related to limits of data resolution and the use of xATP as a reference from which to measure pH (Smith et al., 1990) .
Prominent PME resonances were seen in all tumours. The major constituents of the PME peak, phosphocholine and phosphoethanolamaine represent the anabolic pathway of phospholipid turnover and may relate to proliferation rates of tumours (Daly et al., 1987) . However, no clear relationship between relative PME peak area and grade of malignancy was seen. Further studies directed at the documentation of absolute concentrations of phosphomonoesters will be needed to clarify this issue.
31P metabolite changes were observed before any reduction in tumour size had occurred. As the tumours studied were large and greatly exceeded the size of the surface coils used, we were confident that metabolite changes detected before reductions in tumour size reflected changes occurring in these tumours and were not due to partial volume effects.
In low grade NHL the metabolite changes observed with treatment consisted of increases in Pi and an associated fall in PATP, consistent with the development of an increasing proportion of hypoxic or dying cells within the tumour bulk. These changes were followed by relative increases in PDE.
Glycerophosphorylcholine and glycerophosphorylethanolamine are the major constituents of the PDE peak and represent the catabolic side of phospholipid turnover (Daly et al., 1987) (Wehrle & Glickson, 1986) and in a human rhabdomyosarcoma unresponsive to therapy (Griffiths et al., 1983) . The PDE/PATP ratio may therefore be a more useful indicator of early response to chemotherapy in lymphomas, incorporating the metabolic changes seen in tumour bioenergetics with those of phospholipid turnover.
Increases in the PDE/,ATP ratio have been reported as being associated with a good response to therapy in both subcutaneously implanted tumours in animals and in human tumours (Semmler et al., 1988b) . In vivo MRS does not adequately resolve the individual resonances within the PME and PDE peaks but it has been suggested from high resolution tumour extract studies that it is an increase in the glycerophosphorylcholine component that is responsible for the relative increase in the PDE peak .
In contrast to some recent reports we did not see any alterations in PME in the early studies after commencing therapy (Glaholm et al., 1989; Ng et al., 1989a) . In later studies (approximately 5 months after initially starting treatment) in patients 1 and 4, marked decreases in PME were seen but these probably reflected alterations in the cell populations of the tumours as large reductions in tumour volume had by then occurred.
In this study, therefore, a reproducible slice selective MRS protocol was used to study a homogeneous group of patients. Very consistent metabolite changes were seen in these tumours after commencing chemotherapy. The PDE/PATP metabolite ratio may be a good metabolic indicator of early response to chemotherapy in lymphomas. These studies raise the possibility of performing specifically timed 31p MRS studies during treatment to assess the early efficacy of a treatment protocol in individual patients. The lack of appropriate metabolic change possibly being an indication for alteration in treatment at an earlier time than conventional practice currently allows. Obviously more detailed studies need to be performed in well defined patient groups before the role of 31P MRS in clinical oncology and therapeutics can be fully established, but these preliminary studies illustrate the feasibility and clinical potential of phosphorus MRS.
